Company intelligence / Profile preview

Guizhou Sinorda Biomedicine Co., Ltd.

Guiyang, Guizhou, China

Ownership: Private
Development stage: Other

Overview

Linaprazan glurate (X842) approved for marketing in China for gastroesophageal reflux disease; SND002 (SLN-T) approved for Phase II in Europe for colorectal cancer with IIT results in solid tumors.

Therapeutic areas: OncologyGastroenterology
Modalities: Small moleculeCell therapyOncolytic virusBispecific antibody
Industry: Biotech

Partnerships

Huadong Pharma (commercialization of Linaprazan Glurate)Porton Advanced (CDMO for cell therapies)Rigvir Group (ECHO-7 oncolytic virus licensing)

Beyond the preview

Go deeper on Guizhou Sinorda Biomedicine Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guizhou Sinorda Biomedicine Co., Ltd..

Explore the full profile